Health
Bharat Biotechs Covaxin succeeds in challenge trials on Rhesus monkeys – Business Standard
The results showed protective efficacacy, increasing Sars-CoV-2 specific IgG and neutralising antibodies reducing the replication of the virus in the nasal cavity, throat and lung tissues of monkey
Hyderabad-based Bharat Biotech has released the data from the animal trials of its vaccine candidate, which showed that Covaxin was able to generate ‘robust immune responses’.
The firm said that the vaccine prevented infection and disease in the primates upon high amounts of exposure to live virus Sars-CoV-2. This is called a challenge trial where a participant is exposed deliberately to the pathogen after being given the vaccine shot.
The company tweeted “Bharat Biotech proudly announces th…
-
Noosa News24 hours agoDesign and construction integrity rewarded with national award
-
Noosa News18 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General9 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General15 hours agoCalls for government to ‘get on with’ CSIRO Ginninderra Experiment Station land sale after three-year delay